MONTREAL , Oct. 21, 2024 /PRNewswire/ - Find Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the development of innovative therapies for autoimmune diseases, today announced initiation of dosing in its Phase 1 clinical study of FTX-101 in healthy volunteers.
FTX-101 is a first-in-class therapeutic peptide that modulates the Plexin A1 / Neuropilin 1 transmembrane receptor complex in the brain to promote remyelination. Following completion of the Phase 1 clincal study, Find plans to investigate the use of FTX-101 in individuals with Chronic Optic Neuropathy – a long-term condition due to demyelination in the visual tracts of the brain and optic nerve, with serious effects on visual acuity and perception. The Phase 1 first-in-human study will assess the safety, tolerability, and pharmacokinetics of FTX-101 when administered in healthy volunteers.
The study is being initiated after the US Food and Drug Administration authorized initiation of the study earlier this year. The clinical study consists of two parts. Part 1 is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) study comprised of 40 subjects receiving FTX-101 or placebo while Part 2 is a randomized, double-blind, placebo-controlled, multiple ascending dose (MAD) study that will enroll 24 subjects receiving FTX-101 or placebo.
"The initiation of this study is a significant milestone for both our company and individuals who suffer with Chronic Optic Neuropathy," said Phi.